GILD

132.69

0.79% 1.04

시간 외 거래: 132.80 0.11 +0.08%

길리어드 사이언스 (GILD)

개요 뉴스 가격 이력 옵션 체인 Financials GILD 왜 하락? 토론 예측 주식 분할 배당 이력

전일 마감가:

$131.65

열려 있는:

$130.44

하루 거래량:

5.69M

Relative Volume:

0.88

시가총액:

$164.70B

수익:

$29.45B

순이익/손실:

$8.51B

주가수익비율:

19.56

EPS:

6.7823

순현금흐름:

$9.46B

1주 성능:

+3.87%

1개월 성능:

-5.02%

6개월 성능:

+7.88%

1년 성능:

+27.98%

1일 변동 폭

$130.00

$133.10

1주일 범위

$127.96

$133.10

52주 변동 폭

$95.30

$157.29

길리어드 사이언스 Stock (GILD) Company Profile

명칭

Gilead Sciences Inc

부문

Healthcare (1111)

산업

Drug Manufacturers - General (20)

전화

(650) 574-3000

주소

333 LAKESIDE DR, FOSTER CITY, CA

직원

17,000

트위터

@GileadSciences

다음 수익 날짜

2026-05-07

최신 SEC 제출 서류

GILD's Discussions on Twitter

Compare GILD vs LLY, JNJ, ABBV, AZN, MRK

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
GILD Gilead Sciences Inc	132.69	163.40B	29.45B	8.51B	9.46B	6.7823
LLY Lilly Eli Co	967.93	862.01B	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	224.20	546.90B	96.36B	21.04B	17.80B	8.6488
ABBV Abbvie Inc	208.16	365.43B	62.82B	3.62B	17.82B	2.0331
AZN Astrazeneca Plc	183.46	286.50B	60.48B	10.40B	8.05B	3.3297
MRK Merck Co Inc	113.11	277.02B	65.59B	8.93B	12.36B	3.5532

길리어드 사이언스 Stock (GILD) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-03-10	개시	Jefferies	Buy
2026-02-20	개시	Barclays	Equal Weight
2026-02-11	재확인	Needham	Buy
2026-01-07	재개	UBS	Buy
2025-11-24	재개	Truist	Buy
2025-11-13	개시	Scotiabank	Sector Outperform
2025-08-19	업그레이드	Daiwa Securities	Neutral → Outperform
2025-08-08	업그레이드	Truist	Hold → Buy
2025-07-25	업그레이드	Needham	Hold → Buy
2025-04-22	재개	Cantor Fitzgerald	Overweight
2025-03-04	재확인	Oppenheimer	Outperform
2025-02-18	업그레이드	Deutsche Bank	Hold → Buy
2025-02-13	업그레이드	DZ Bank	Hold → Buy
2025-01-10	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	재개	BofA Securities	Buy
2024-11-15	개시	Wolfe Research	Outperform
2024-11-14	개시	Citigroup	Buy
2024-11-08	다운그레이드	Maxim Group	Buy → Hold
2024-10-21	업그레이드	Leerink Partners	Market Perform → Outperform
2024-10-17	개시	Bernstein	Outperform
2024-10-07	업그레이드	Wells Fargo	Equal Weight → Overweight
2024-07-08	업그레이드	Raymond James	Mkt Perform → Outperform
2024-05-01	재확인	Maxim Group	Buy
2024-04-24	업그레이드	HSBC Securities	Reduce → Hold
2024-02-22	다운그레이드	Truist	Buy → Hold
2023-11-09	개시	Deutsche Bank	Hold
2023-09-08	업그레이드	BofA Securities	Neutral → Buy
2023-09-06	개시	HSBC Securities	Reduce
2023-07-24	재확인	Barclays	Equal Weight
2023-05-16	업그레이드	BMO Capital Markets	Market Perform → Outperform
2023-04-28	재개	Piper Sandler	Overweight
2023-01-03	다운그레이드	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	재개	BofA Securities	Neutral
2022-12-09	다운그레이드	DZ Bank	Buy → Hold
2022-10-31	업그레이드	Barclays	Underweight → Equal Weight
2022-10-28	재확인	BMO Capital Markets	Market Perform
2022-10-28	재확인	Cowen	Outperform
2022-10-28	재확인	JP Morgan	Overweight
2022-10-28	재확인	Jefferies	Buy
2022-10-28	업그레이드	Piper Sandler	Neutral → Overweight
2022-10-28	재확인	RBC Capital Mkts	Outperform
2022-10-28	업그레이드	Truist	Hold → Buy
2022-10-28	재확인	Wells Fargo	Equal Weight
2022-10-04	업그레이드	JP Morgan	Neutral → Overweight
2022-07-13	개시	Cantor Fitzgerald	Neutral
2022-05-23	개시	SVB Leerink	Mkt Perform
2022-02-28	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2022-02-02	재확인	BMO Capital Markets	Outperform
2022-02-02	재확인	BofA Securities	Neutral
2022-02-02	재확인	RBC Capital Mkts	Outperform
2022-02-02	재확인	Truist	Hold
2022-02-02	재확인	Wells Fargo	Equal Weight
2022-01-28	업그레이드	Argus	Hold → Buy
2022-01-06	다운그레이드	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	재개	Wells Fargo	Equal Weight
2021-12-06	개시	Goldman	Neutral
2021-11-19	업그레이드	BMO Capital Markets	Market Perform → Outperform
2021-11-19	재개	Piper Sandler	Neutral
2021-10-20	재개	Cowen	Outperform
2021-07-30	재확인	BMO Capital Markets	Market Perform
2021-07-30	재확인	RBC Capital Mkts	Outperform
2021-04-01	업그레이드	Bernstein	Mkt Perform → Outperform
2021-03-30	업그레이드	Redburn	Neutral → Buy
2021-01-19	업그레이드	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	업그레이드	Guggenheim	Neutral → Buy
2020-11-03	재개	Morgan Stanley	Equal-Weight
2020-10-28	개시	UBS	Neutral
2020-09-30	재개	Jefferies	Buy
2020-09-15	업그레이드	Maxim Group	Hold → Buy
2020-07-31	재확인	Credit Suisse	Neutral
2020-07-31	재확인	Morgan Stanley	Equal-Weight
2020-07-31	재확인	Piper Sandler	Overweight
2020-07-31	재확인	RBC Capital Mkts	Outperform
2020-07-31	재확인	SunTrust	Hold
2020-07-31	재확인	Wells Fargo	Equal Weight
2020-07-20	업그레이드	Credit Suisse	Underperform → Neutral
2020-06-03	업그레이드	SVB Leerink	Mkt Perform → Outperform
2020-05-26	업그레이드	SunTrust	Sell → Hold
2020-05-01	다운그레이드	JP Morgan	Overweight → Neutral
2020-05-01	다운그레이드	Raymond James	Outperform → Mkt Perform
2020-05-01	다운그레이드	SunTrust	Hold → Sell
2020-04-27	다운그레이드	UBS	Buy → Neutral
2020-04-20	다운그레이드	BMO Capital Markets	Outperform → Market Perform
2020-04-20	다운그레이드	Wells Fargo	Overweight → Equal Weight
2020-04-17	다운그레이드	CFRA	Hold → Sell

모두보기

길리어드 사이언스 주식(GILD)의 최신 뉴스

04:54 AM

Gilead Shareholders Back Board, Pay Plans at 2026 Meeting - TipRanks

04:54 AM

03:21 AM

Gilead Sciences Completes Acquisition of Arcellx to Strengthen Oncology Portfolio - Oncodaily

03:21 AM

09:15 AM

Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance

09:15 AM

08:14 AM

Varma Mutual Pension Insurance Co Cuts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

08:14 AM

08:04 AM

Gilead Sciences to Acquire Tubulis to Advance Targeted Cancer Therapies - The Healthcare Technology Report.

08:04 AM

07:54 AM

Gilead Sciences, Inc. $GILD Shares Bought by Triasima Portfolio Management inc. - MarketBeat

07:54 AM

07:11 AM

Intact Investment Management Inc. Has $10.36 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

07:11 AM

05:00 AM

Can You Sue A Drug Company For Not Inventing Faster? - Forbes

05:00 AM

May 03, 2026

Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences (RCUS)? - simplywall.st

May 03, 2026

Benjamin Edwards Inc. Has $16.60 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

May 03, 2026

May 02, 2026

FDA Priority Review For New HIV Combo Might Change The Case For Investing In Gilead Sciences (GILD) - simplywall.st

May 02, 2026

Strs Ohio Reduces Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

May 02, 2026

PFA Pension Forsikringsaktieselskab Purchases Shares of 826,930 Gilead Sciences, Inc. $GILD - MarketBeat

May 02, 2026

Robertson Stephens Wealth Management LLC Has $6.27 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat

May 02, 2026

Gilead Sciences, Inc. $GILD Stock Holdings Increased by Sigma Planning Corp - MarketBeat

May 02, 2026

Gilead’s HIV Priority Review And Arcellx Deal Refocus Long‑Term Story - Yahoo Finance

May 02, 2026

May 01, 2026

The Freelux Project Announces “The Butch Queen’s Brunch & Conversations Tour” Powered by Gilead Sciences - GLAAD

May 01, 2026

Gilead Sciences, Inc. $GILD Shares Sold by New York State Teachers Retirement System - MarketBeat

May 01, 2026

Oppenheimer & Co. Inc. Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat

May 01, 2026

Jennison Associates LLC Buys 741,044 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

May 01, 2026

US Bancorp DE Has $105.44 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

May 01, 2026

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences - The AI Journal

May 01, 2026

Danske Bank A S Sells 45,529 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

May 01, 2026

Fifth Third Bancorp Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat

May 01, 2026

GC Wealth Management RIA LLC Reduces Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

May 01, 2026

Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S Cash Flow – TSX:GILD - TradingView

May 01, 2026

Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S Revenue Breakdown – TSX:GILD - TradingView

May 01, 2026

Apr 30, 2026

Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know - Yahoo Finance

Apr 30, 2026

Gilead Sciences Annual Meeting: Directors, Pay Win Big; Pipeline Launches and Acquisitions Highlighted - MarketBeat

Apr 30, 2026

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Apr 30, 2026

Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now? - Insider Monkey

Apr 30, 2026

[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir - European AIDS Treatment Group

Apr 30, 2026

Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish? - Barchart.com

Apr 30, 2026

Gilead Sciences, Inc. $GILD Shares Sold by Verity Asset Management Inc. - MarketBeat

Apr 30, 2026

Gilead Sciences, Inc. $GILD Position Trimmed by State of New Jersey Common Pension Fund D - MarketBeat

Apr 30, 2026

Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

Apr 30, 2026

Guardian Large Cap Disciplined Value VIP Fund's Gilead Sciences Inc(GILD) Holding History - GuruFocus

Apr 30, 2026

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Apr 30, 2026

FY2026 EPS Estimates for Gilead Sciences Reduced by Analyst - MarketBeat

Apr 30, 2026

Kymera Therapeutics (NASDAQ: KYMR) Q1 2026 results and $45M Gilead milestone - Stock Titan

Apr 30, 2026

Is It Time To Revisit Gilead Sciences (GILD) After Recent Share Price Pullback - Yahoo Finance

Apr 30, 2026

Apr 29, 2026

Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus

Apr 29, 2026

Gilead Sciences (NASDAQ:GILD) CEO Sells $1,291,600.00 in Stock - MarketBeat

Apr 29, 2026

Vanguard reports 93.3M-share, 7.51% stake in Gilead Sciences (NASDAQ: GILD) - Stock Titan

Apr 29, 2026

Gilead Sciences CEO Daniel O’Day sells over $1.29m in stock - Investing.com Nigeria

Apr 29, 2026

Gilead (NASDAQ: GILD) CEO sells 10,000 shares in planned trade - Stock Titan

Apr 29, 2026

Assessing Whether Gilead Sciences (GILD) Looks Undervalued After Recent Share Price Performance - simplywall.st

Apr 29, 2026

Gilead Sciences Stock: Three Acquisitions, Four Launches, and a 20% Discount to Wall Street’s Target - TIKR.com

Apr 29, 2026

U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir - BioSpace

Apr 29, 2026

GILD: Gilead's New HIV Treatment Gains FDA Acceptance - GuruFocus

Apr 29, 2026

Kymera Therapeutics earnings on deck after Gilead deal milestone By Investing.com - Investing.com Nigeria

Apr 29, 2026